Ultragenyx Pharmaceutical Shares Rise 14% Following Interim Data from Studies

By Denny Jacob Ultragenyx Pharmaceutical shares rose 14% to $38.18 following interim data from ongoing studies. The stock is down 18% on the year so far. The...

Related Keywords

Denny Jacob ,Emil Kakkis , ,Osteogenesis Imperfecta ,Chief Executive Emil ,Article Normal ,Pharmaceuticals ,Healthcare Life Sciences ,Financial Performance ,Corporate Industrial News ,Equity Markets ,Commodity Financial Market News ,Content Types ,Factiva Filters ,C Amp Ampe Exclusion Filter ,C Amp Ampe Industry News Filter ,Synd ,Ultragenyx Pharmaceutical ,Rare ,Corporate ,Industrial News ,Commodity ,Financial Market News ,Healthcare ,Life Sciences ,